Home/Filings/4/0001209191-20-055423
4//SEC Filing

Vivo Capital IX, LLC 4

Accession 0001209191-20-055423

CIK 0001819790other

Filed

Oct 19, 8:00 PM ET

Accepted

Oct 20, 7:58 PM ET

Size

14.8 KB

Accession

0001209191-20-055423

Insider Transaction Report

Form 4
Period: 2020-10-20
Transactions
  • Conversion

    Common Stock

    2020-10-20+2,780,7542,780,754 total
  • Conversion

    Common Stock

    2020-10-20+214,2812,995,035 total
  • Purchase

    Common Stock

    2020-10-20$16.00/sh+250,000$4,000,0003,245,035 total
  • Conversion

    Series B Preferred Stock

    2020-10-202,780,7540 total
    Common Stock (2,780,754 underlying)
  • Conversion

    Series C Preferred Stock

    2020-10-20214,2810 total
    Common Stock (214,281 underlying)
Transactions
  • Purchase

    Common Stock

    2020-10-20$16.00/sh+250,000$4,000,0003,245,035 total
  • Conversion

    Common Stock

    2020-10-20+2,780,7542,780,754 total
  • Conversion

    Common Stock

    2020-10-20+214,2812,995,035 total
  • Conversion

    Series B Preferred Stock

    2020-10-202,780,7540 total
    Common Stock (2,780,754 underlying)
  • Conversion

    Series C Preferred Stock

    2020-10-20214,2810 total
    Common Stock (214,281 underlying)
Footnotes (2)
  • [F1]Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
  • [F2]The shares are held directly by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the general partner of Vivo Capital Fund IX, L.P. As the managing members of Vivo Capital IX, LLC, Frank Kung, Edgar Engleman, Shan Fu, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Vivo Capital Fund IX, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

Issuer

Tarsus Pharmaceuticals, Inc.

CIK 0001819790

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001750698

Filing Metadata

Form type
4
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 7:58 PM ET
Size
14.8 KB